ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

NewLink and Tokai will cut jobs

by Ann M. Thayer
August 8, 2016 | APPEARED IN VOLUME 94, ISSUE 32

Setbacks in late-stage cancer clinical trials have led to job cuts at NewLink Genetics and Tokai Pharmaceuticals. NewLink will cut about 100 jobs, or more than 40% of its staff, as it winds down work on the cellular immunotherapy algenpantucel-L, which failed to show any effect against pancreatic cancer. The firm will focus on developing its IDO pathway inhibitor, indoximod, in multiple cancers. Likewise, Tokai will reduce its workforce by about 60% to just 10 full-time employees. The company recently halted a Phase III prostate cancer trial of its small-molecule drug galeterone. The company says it will explore options for galeterone.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment